There are 2949 resources available
1422MO - Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-low, advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Results of the exploratory cohorts in the phase II, multicenter, open-label DESTINY-Gastric01 study
Presenter: Kensei Yamaguchi
Session: Mini Oral - Gastrointestinal tumours, non-colorectal
Resources:
Abstract
Slides
Webcast
1166MO - Clinical evaluation of serum succinate levels as a new biomarker in SDH-related paragangliomas and pheochromocytomas
Presenter: Constance Lamy
Session: Mini Oral - NETs and endocrine tumours
Resources:
Abstract
Slides
Webcast
1161MO - Lanreotide autogel (LAN) and temozolomide (TMZ) combination therapy in progressive thoracic neuroendocrine tumours (TNETs): ATLANT study results
Presenter: Piero Ferolla
Session: Mini Oral - NETs and endocrine tumours
Resources:
Abstract
Slides
Webcast
1162MO - Efficacy and safety of lanreotide autogel (LAN) 120 mg every 14 days in progressive pancreatic or midgut neuroendocrine tumours (NETs): CLARINET FORTE study results
Presenter: Marianne Pavel
Session: Mini Oral - NETs and endocrine tumours
Resources:
Abstract
Slides
Webcast
LBA48 - Clinical efficacy and immunity of combination therapy with nivolumab and IDO/PD-L1 peptide vaccine in patients with metastatic melanoma: A phase I/II trial
Presenter: Inge-Marie Svane
Session: Mini Oral - Melanoma and other skin tumours
Resources:
Abstract
Slides
Webcast
LBA56 - ORIENT-12: Sintilimab plus gemcitabine and platinum (GP) as first-line (1L) treatment for locally advanced or metastatic squamous non-small-cell lung cancer (sqNSCLC)
Presenter: Caicun Zhou
Session: Mini Oral - NSCLC, metastatic
Resources:
Abstract
Slides
Webcast
LBA57 - MHC-II antigen presentation pathway as a predictive biomarker for sintilimab plus chemotherapy in first-line treatment of locally advanced or metastatic non-squamous non-small cell lung cancer (nsq-NSCLC)
Presenter: Yunpeng Yang
Session: Mini Oral - NSCLC, metastatic
Resources:
Abstract
Slides
Webcast
1260MO - Activity of OSE-2101 in HLA-A2+ non-small cell lung cancer (NSCLC) patients after failure to immune checkpoint inhibitors (ICI): Step 1 results of phase III ATALANTE-1 randomised trial
Presenter: Giuseppe Giaccone
Session: Mini Oral - NSCLC, metastatic
Resources:
Abstract
Slides
Webcast
LBA58 - ORR in patients receiving nivolumab plus radiotherapy in advanced non-small cell lung cancer: First results from the FORCE trial
Presenter: Farastuk Bozorgmehr
Session: Mini Oral - NSCLC, metastatic
Resources:
Abstract
Slides
Webcast
533MO - Phase Ib study of BI 836880, a VEGF/Ang2-blocking nanobody®, in combination with BI 754091, an anti-PD-1 antibody: Initial results in patients (pts) with solid tumours
Presenter: Nicolas Girard
Session: Mini Oral - Developmental therapeutics
Resources:
Abstract
Slides
Webcast